Annual Sales of Brilinta reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Brilinta Market Competitive Landscape The competitive landscape of the Brilinta market is characterized by a predominantly consolidated structure, with a few global pharmaceutical giants commanding significant market share through extensive R&D investments, strategic alliances, and robust manufacturing capabilities. Worldwide Brilinta Market 2026 Global Brilinta Market Size, Share & Industry Analysis, By Dosage Strength (90mg Tablets, 60mg Tablets), By Indication (Acute Coronary Syndrome, Coronary Artery Disease), and Regional Forecast 2026-2032. Brilinta Market size was valued at USD 2.14 Bn in 2025, and the Brilinta Market revenue is expected to grow at a CAGR of 9% The Brilinta Market Analysis market report covers financials, market share, SWOTs, and responses to Tariffs, while providing global, regional, and country-level forecasts supported by value chain, patent analysis, and a competitive matrix serving as a key resource for stakeholders and investors. The Brilinta market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. The Brilinta market was valued at $6.8 billion in 2025 and is projected to reach $11.2 billion by 2034, growing at 5.8% CAGR. Global analysis of antiplatelet therapy market trends. Brilinta, a cardiometabolic drug once projected as a blockbuster but which underperformed expectations, is also losing U.S. patent protection soon (2). To illustrate the prominence of drugs on this list, last year's leader was Bristol Myers Squibb's Sprycel, with $1.45 billion in prior-year U.S. sales. Brilinta Market Overview The global Brilinta market size was valued at USD 2248.57 million in 2026 and is expected to reach USD 2440.82 million in 2027, further expanding to USD 4706.23 million by 2035, growing at a CAGR of 8.55% during the forecast period. The Brilinta Market was valued at USD 1,506.2 million in 2024 and is projected to reach USD 2,329.1 million by 2032, growing at a CAGR of 5.6% during the forecast period. Brilinta Market Insights The global Brilinta market size was valued at USD 1.85 billion in 2025. The market is projected to grow from USD 1.98 billion in 2026 to USD 3.42 billion by 2034, exhibiting a CAGR of 7.1% during the forecast period. Brilinta, the trade name for ticagrelor, is an antiplatelet medication developed by AstraZeneca and primarily used to prevent cardiovascular events such … Brilinta (ticagrelor) is used to prevent heart attack, stroke, or other vascular events in people who have had a recent heart attack or who have severe chest pain. Brilinta is an antiplatelet drug, which works by helping stop platelets from forming blood clots. The most common form of Brilinta is a 90mg tablet. It is also available as a 60mg … To focus on the key Brilinta Market manufacturers, defining, describing, and analyzing their sales volume, value, market share, market competition landscape, SWOT analysis, and development plans. To analyze the Brilinta Market with respect to individual growth trends, prospects, and their contribution to the total market. BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1 … Annual Sales of Ticagrelor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Brilinta Market Overview The global Brilinta Market size is projected to grow from USD 2248.57 million in 2026 to USD 2440.69 million in 2027, reaching USD 4705.16 million by 2035, expanding at a CAGR of 8.55% during the forecast period. Compare prices and print coupons for Ticagrelor at major pharmacies. Find savings tips for this medication on GoodRx. Key Takeaways Ticagrelor holds a substantial share of the antiplatelet market, with sales driven by efficacy and guideline endorsement. Patent expirations scheduled for 2026-2027 will reduce prices significantly. While current prices are stable, generics will exert downward pressure, especially in price-sensitive markets. And an FDA thumbs-up for Brilinta treatment beyond the one-year mark could actually foster more use in the drug's current eligible patient pool, Marc Ditmarsch, AstraZeneca's global lead for … Brilinta (ticagrelor) is a brand-name antiplatelet drug that's been approved by the Food and Drug Administration (FDA) to reduce the risk of certain complications of acute coronary syndrome (ACS), including heart attack and stroke. AstraZeneca first manufactured Brilinta in 2011. In 2018, the FDA approved the manufacture of generic Brilinta, and now more than a dozen pharmaceutical companies … Sales of Brilinta slid 7% to $385 million in Q3 due to COVID-19 and a wholesaler inventory adjustment in China after the drug was found to be squaring off against local generics for a place in the … Transfer your prescription for BRILINTA 90 MG TAB on Amazon Pharmacy. FREE SHIPPING for Prime members. Searching News Database: BRILINTA HSMN NewsFeed – 14 Apr 2025 CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America Devices Personnel HSMN NewsFeed – 12 May 2020 CytoSorb (R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery Chapter 3, the Brilinta competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Brilinta breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031. AstraZeneca's Parthenon program for Brilinta has been a hit-and-miss affair despite $3.7 billion in R&D costs. (AstraZeneca) With a series of late-stage trial readouts in the past few years … It's a blow to AZ, particularly after Brilinta had begun to gather speed. Stepped-up marketing and one new indication helped boost sales by 48% for the first half of this year. Compare Brilinta 90 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for Brilinta. Discounts up to 80% off the retail price. The global Brilinta market size is expected to reach $ million by 2031, rising at a market growth of %CAGR during the forecast period (2025-2031). Ticagrelor (Generic for Brilinta) Why does my medication look different? Product images are for illustrative purposes only. We can not guarantee a specific manufacturer when you place an order. The medication you receive may look different but the drug, strength, and ingredients are the same. Soon after CEO Pascal Soriot took over at AstraZeneca in 2012, he declared Brilinta to be a big opportunity for growth. That was a surprise, given the blood thinner's laggardly sales since its … Brilinta (ticagrelor), developed by AstraZeneca, is a P2Y12 platelet inhibitor approved for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or prior myocardial infarction (MI). It competes primarily with clopidogrel, prasugrel, and newer antiplatelet agents. Compare generic Brilinta (ticagrelor) 60 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for generic Brilinta (ticagrelor). Discounts up to 80% off the retail price. Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. Find information about how eligible patients can get the BRILINTA® (ticagrelor) savings card. Compare Brilinta prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. The current wholesale acquisition cost for Brilinta (NDC 0186-0776-60) is $7.41915 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Sep 23, 2026. As a a human prescription drug provided by Astrazeneca Pharmaceuticals Lp, this medication is distributed in a 60 TABLET in 1 BOTTLE configuration. The pricing data is derived … Johnson & Johnson, Amgen, Regeneron, Novartis and other Big Pharma players are facing down sizable U.S. losses of exclusivity in 2025. Current NADAC wholesale price for Brilinta: $7.42045 per EA. Review historical pricing trends, effective dates, and pharmacy acquisition benchmarks for NDC 0186 Wondering when a generic version of Brilinta will be available? Get details on FDA approval status, generic manufacturers, and patent expirations.
